The patent for Rexulti (brexpiprazole) is set to expire in 2034 [1][2]. However, this expiration date may be subject to change due to potential patent challenges or extensions [3].
What is Rexulti used for?
Rexulti is a medication approved for the treatment of schizophrenia in adults and as an adjunctive therapy for major depressive disorder in adults [1][4].
What are the key patents for Rexulti?
The primary patent protecting Rexulti is U.S. Patent No. 8,133,997, which is set to expire in 2034 [1][2]. There may be other related patents that also contribute to the drug's exclusivity [3].
Can generics be produced before the patent expires?
Generally, generic versions of a drug cannot be manufactured or sold in the United States until the relevant patents have expired or have been invalidated [3]. However, companies may file abbreviated new drug applications (ANDAs) to challenge existing patents and seek early market entry for their generic versions [5].
What happens after the patent expires?
Once the patent protection for Rexulti ends, other pharmaceutical companies may be able to produce and market generic versions of the drug [3]. This typically leads to increased competition and a decrease in the price of the medication for consumers [5].
Where can I find more information on drug patents?
DrugPatentWatch.com provides comprehensive data on drug patents, including expiration dates, patent litigation, and exclusivity periods for various medications [3].